MRKR Marker Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRKR

Price (delayed)

$1.24

Market cap

$20.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.41

Enterprise value

$8.75M

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 53
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 35

Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company ...

Highlights
Marker Therapeutics's quick ratio has soared by 78% YoY and by 20% from the previous quarter
The EPS has soared by 70% year-on-year and by 33% since the previous quarter
Marker Therapeutics's equity has increased by 16% YoY but it has decreased by 12% from the previous quarter
MRKR's revenue is down by 44% year-on-year
Marker Therapeutics's gross profit has decreased by 44% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.markertherapeutics.com
Peers: VIVS ORIC ORMP

Key stats

What are the main financial stats of MRKR

MRKR stock price

How has the Marker Therapeutics stock price performed over time
Intraday
1.64%
1 week
8.77%
1 month
-10.79%
1 year
45.27%
YTD
-16.78%
QTD
-15.65%

Financial performance

How have Marker Therapeutics's revenue and profit performed over time
Revenue
$2.34M
Gross profit
$2.34M
Operating income
-$10.71M
Net income
-$8.71M
Gross margin
100%
Net margin
-372.7%
MRKR's revenue is down by 44% year-on-year
Marker Therapeutics's gross profit has decreased by 44% YoY
MRKR's net income is up by 40% year-on-year and by 20% since the previous quarter
Marker Therapeutics's operating income has increased by 34% YoY and by 19% from the previous quarter

Price vs fundamentals

How does MRKR's price correlate with its fundamentals

Growth

What is Marker Therapeutics's growth rate over time

Valuation

What is Marker Therapeutics stock price valuation
P/E
N/A
P/B
1.7
P/S
10.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.75
The EPS has soared by 70% year-on-year and by 33% since the previous quarter
The P/B is 19% above the last 4 quarters average of 1.4 but 12% below the 5-year quarterly average of 1.9
Marker Therapeutics's equity has increased by 16% YoY but it has decreased by 12% from the previous quarter
MRKR's revenue is down by 44% year-on-year
MRKR's P/S is 20% above its last 4 quarters average of 8.4 but 8% below its 5-year quarterly average of 11.0

Efficiency

How efficient is Marker Therapeutics business performance
The ROE has soared by 50% year-on-year and by 22% since the previous quarter
The ROA has grown by 47% YoY and by 20% from the previous quarter
The ROS is up by 20% since the previous quarter but it is down by 7% year-on-year

Dividends

What is MRKR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRKR.

Financial health

How did Marker Therapeutics financials performed over time
Marker Therapeutics's quick ratio has soared by 78% YoY and by 20% from the previous quarter
The current ratio has soared by 75% YoY and by 26% from the previous quarter
The company's debt is 100% lower than its equity
Marker Therapeutics's equity has increased by 16% YoY but it has decreased by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.